A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.
Recruiting in Palo Alto (17 mi)
+10 other locations
HY
Overseen byHelen Yu, MD
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase < 1
Waitlist Available
Sponsor: Memorial Sloan Kettering Cancer Center
No Placebo Group
Breakthrough Therapy
Trial Summary
What is the purpose of this trial?
The purpose of this study is to assess whether dacomitinib after osimertinib is effective in participants with metastatic EGR-mutant lung cancers.
Research Team
HY
Helen Yu, MD
Principal Investigator
Memorial Sloan Kettering Cancer Center
Eligibility Criteria
Inclusion Criteria
Age >/= 18 years old
Somatic activating mutation in EGFR in a tumor biopsy or plasma cfDNA liquid biopsy
Karnofsky performance status (KPS) >/= 70%
See 14 more
Exclusion Criteria
You still have side effects from a previous treatment that are worse than mild.
You have had radiation treatment within one week before starting the study.
Any major surgery within 1 weeks of starting treatment on protocol.
See 4 more
Treatment Details
Interventions
- Dacomitinib (Tyrosine Kinase Inhibitor)
- Osimertinib (Tyrosine Kinase Inhibitor)
Participant Groups
2Treatment groups
Experimental Treatment
Group I: Cohort 2: Participants treated with dacomitinib in combination with osimertinibExperimental Treatment2 Interventions
Participants in this cohort have a secondary acquired EGFR mutation in addition to the sensitizing mutation
Group II: Cohort 1: Participants treated with dacomitinib aloneExperimental Treatment1 Intervention
Participants in this cohort have a somatic activating mutation in EGFR in a tumor biopsy or plasma cfDNA liquid biopsy.
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
Memoral Sloan Kettering Basking RidgeBasking Ridge, NJ
Memoral Sloan Kettering MonmouthMiddletown, NJ
Memoral Sloan Kettering WestchesterHarrison, NY
Memorial Sloan Kettering CommackCommack, NY
More Trial Locations
Loading ...
Who Is Running the Clinical Trial?
Memorial Sloan Kettering Cancer Center
Lead Sponsor
Trials
1998
Patients Recruited
602,000+